According to the Complaint, LogicBio Therapeutics, Inc. purports to be a genome editing company, focused on developing medicines to treat rare diseases in patients with unmet medical need using the GeneRide technology platform. The Company’s lead product candidate is LB-001 for the treatment of Methylmalonic Acidemia (“MMA”), a life-threatening disease that presents at birth.

The Complaint alleges that Defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) LogicBio’s behind-schedule and rushed Investigational New Drug (“IND”) submission of LB-001 did not answer certain pertinent clinical and nonclinical questions; (2) as a result, the U.S. Food and Drug Administration was likely to hold or deny the IND submission of LB-001 for treatment of methylmalonic acidemia (MMA); and (3) as a result, Defendants’ statements about its business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

On June 2, 2020, the Court granted Defendants' Motion to Transfer the case to the District of Massachusetts. The case was transferred in to the District of Massachusetts on June 18 under Docket 20-CV-11158.

This case was voluntarily dismissed on April 5, 2021.